In combination with the association of LAT2 expression in tumor tissue with improved survival in patients without metastasis, LAT2-mediated doxorubicin transport could mechanistically explain the association of genetic variation in SLC7A8 that is associated with EDP in patients with osteosarcoma. The gene discussed is LAT2; the disease is osteosarcoma.